Companies: 10,795·Total market cap: $144.5T
Sabra Health Care REIT, Inc.

Sabra Health Care REIT, Inc.

SBRANASDAQReal Estate● Active
$18.16
$-0.30(-1.63%)
Market Cap$4.6B
P/E Ratio
52W High$21.28
52W Low$17.17
Overview

Sabra Health Care REIT, Inc. (SBRA) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

sbra · stock forecast · 29 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 29 Wall Street analysts in the past 3 months

SellBuy

Hold

29 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
11
Hold
16
Sell
2
Strong Sell
0
Total: 29 · Buy rate: 37.9%

12-Month Price Target

High

$22.00

Consensus

$21.80

+21.5% upside

Low

$21.00

Median: $22 · Last Close: $17.95

The Sabra Health Care REIT, Inc. (SBRA) analyst consensus is Hold, based on ratings from 29 Wall Street analysts over the past 3 months. The average 12-month SBRA price target is $21.80, representing +21.5% upside from the current price of $17.95.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $22 (21.5%)

Consensus Target

$21.80

21.5% upside

High Target

$22

22.6%

Low Target

$21

17.0%

Current Price

$17.95

as of today

Based on analyst price targets, the SBRA stock price prediction for the next 12 months ranges from $21 to $22. The consensus SBRA price forecast of $21.80 implies 21.5% upside from the current price of $17.95.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$17.055.00%

1-day model range: $16.99–$17.1. Peak: $17.1 (-5.00%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$23+27.0%
2028$26+47.6%
2029$29+61.9%
2030$31+71.4%
2031+77.4%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

7%0%93%
1Buy
0Neutral
13Sell
RSI (14)20.2Oversold
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · SBRA · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$18.15SELL
MA 10$19.12SELL
MA 20$20.01SELL
MA 50$20.12SELL
MA 100$19.94SELL
MA 200$19.34SELL
Current $SBRA · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$18.33SELL
EMA 10$18.90SELL
EMA 20$19.52SELL
EMA 50$19.94SELL
EMA 100$19.84SELL
EMA 200$19.39SELL
Current $SBRA · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Wells Fargo2026-06-01
Maintains
OverweightOverweight
Scotiabank2026-05-21
Maintains
Sector PerformSector Perform
UBS2026-05-13
Maintains
NeutralNeutral
Cantor Fitzgerald2026-05-11
Maintains
NeutralNeutral
Wells Fargo2026-03-26
Maintains
OverweightOverweight
Truist Securities2026-03-13
Maintains
HoldHold
Scotiabank2026-03-02
Maintains
Sector PerformSector Perform
UBS2026-02-19
Maintains
NeutralNeutral
Citigroup2026-02-18
Maintains
BuyBuy
Citizens2026-02-18
Maintains
Market OutperformMarket Outperform

Wall Street analysts have recently issued updated ratings on Sabra Health Care REIT, Inc. (SBRA) stock. Of the recent 186 rating actions, 32 were upgrades and 30 were downgrades. 29 analysts currently cover SBRA.

Analyst Recommendation Trends

Buy ratings11
Hold ratings00
Sell ratings00

SBRA analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$898M

↓ 9.6% YoY

Revenue Next Year

$976M

↑ 8.7% YoY

EPS This Year

$0.67

EPS Next Year

$0.75

↑ 10.9% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast SBRA EPS of $0.67 for the current fiscal year, based on estimates from 4 analysts. The SBRA revenue forecast is $898M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The SBRA stock forecast is supported by two independent data sources: analyst consensus ratings from 29 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus SBRA price target is $21.80 (+21.5% upside), with an analyst consensus of Hold.

The SBRA short-term stock prediction for tomorrow is $17.05 (-5.00%). The SBRA stock price prediction for 2027 estimates an average of $23. The SBRA stock prediction for 2030 projects a range of $30–$32.

Sabra Health Care REIT, Inc. trades on NASDAQ under the ticker SBRA. The SBRA stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 38% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

SBRA forecast · 8 questions

According to 29 Wall Street analysts, the average 12-month SBRA price target is $21.80, with a high forecast of $22.00 and a low of $21.00. The median price target is shown in the chart above when available. This implies +21.5% potential upside from the current price of $17.95.

SBRA price targetWhat is SBRA price targetSBRA analyst price targetSBRA 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.